论文部分内容阅读
酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)纳入Ph阳性急性淋巴细胞白血病(Ph+ALL)的治疗显著改善了疗效,近95%的患者达到完全缓解(CR),3年生存率可达55%。这种新的治疗方式,不仅为CR期患者提供了接受异基因造血干细胞移植(Allo-HSCT)更多的机会,也有助于延长不能移植患者的长期缓解。虽然在Ph+ALL治疗的某些策略上已经逐步达到共识,但目前对如何选择最适合的诱导和巩固治疗,AlloHSCT移植与TKIs为基础的维持治疗的短期和最终获益,如何正确监测BCR-ABL和使用TKIs,对不能移植患者的最有效的治疗方案是什么,以及
The treatment of patients with Ph-ALL acute lymphoblastic leukemia (Ph + ALL) significantly improved the efficacy of tyrosine kinase inhibitors (TKIs), achieving complete remission (CR) in nearly 95% of patients and a 3-year survival rate of up to 55%. This new treatment not only provides CR patients with more opportunities for allogeneic hematopoietic stem cell transplantation (Allo-HSCT), but also helps prolong the long-term remission in non-transplant patients. Although consensus has been reached on some strategies for treatment of Ph + ALL, the current short and long-term benefit of AlloHSCT transplantation and TKIs-based maintenance therapy on how to choose the most appropriate induction and consolidation therapy and how to properly monitor BCR- ABL and TKIs, what are the most effective treatments for patients who can not be grafted, and